FLT4 and myocardial infarction: In mouse models of myocardial infarction, treatment with adrenomedullin or a recombinant form of VEGFC that selectively activates VEGFR3 has led to the resolution of disease-induced edema and inflammatory factors, successfully averting cardiac fibrosis and dysfunction (18, 106).